ZA201306402B - Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators) - Google Patents

Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)

Info

Publication number
ZA201306402B
ZA201306402B ZA2013/06402A ZA201306402A ZA201306402B ZA 201306402 B ZA201306402 B ZA 201306402B ZA 2013/06402 A ZA2013/06402 A ZA 2013/06402A ZA 201306402 A ZA201306402 A ZA 201306402A ZA 201306402 B ZA201306402 B ZA 201306402B
Authority
ZA
South Africa
Prior art keywords
azacycles
condensed
processes
preparation
crystalline forms
Prior art date
Application number
ZA2013/06402A
Other languages
English (en)
Inventor
Anthony C Blackburn
Robert M Jones
Biman B Pal
Sangdon Han
Jaimie Karyn Rueter
Anthonio Garrido Montalban
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of ZA201306402B publication Critical patent/ZA201306402B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2013/06402A 2011-02-25 2013-08-23 Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators) ZA201306402B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US201161448542P 2011-03-02 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (1)

Publication Number Publication Date
ZA201306402B true ZA201306402B (en) 2022-03-30

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/06402A ZA201306402B (en) 2011-02-25 2013-08-23 Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)

Country Status (20)

Country Link
US (4) US9458136B2 (enExample)
EP (3) EP2678330A1 (enExample)
JP (1) JP5945554B2 (enExample)
KR (1) KR102036932B1 (enExample)
CN (1) CN103608343B (enExample)
AU (1) AU2012222146B2 (enExample)
BR (1) BR112013021549B1 (enExample)
CA (1) CA2827057C (enExample)
CL (1) CL2013002436A1 (enExample)
CO (1) CO6852066A2 (enExample)
DK (1) DK3395812T3 (enExample)
EA (1) EA035989B1 (enExample)
ES (1) ES2932441T3 (enExample)
IL (1) IL227782A (enExample)
MX (1) MX346533B (enExample)
MY (1) MY165767A (enExample)
PH (1) PH12013501726A1 (enExample)
SG (1) SG192817A1 (enExample)
WO (1) WO2012116276A1 (enExample)
ZA (1) ZA201306402B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2470508A1 (en) * 2009-08-28 2012-07-04 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX392150B (es) 2011-02-25 2025-03-21 Arena Pharm Inc Moduladores de receptores canabinoides.
JP5945554B2 (ja) * 2011-02-25 2016-07-05 アリーナ ファーマシューティカルズ, インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス(カンナビノイド受容体モジュレーター)
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
CN109310673A (zh) * 2016-04-10 2019-02-05 艾尼纳制药公司 用选择性cb2受体激动剂治疗的方法
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
US20200078358A1 (en) * 2017-05-08 2020-03-12 Arena Pharmaceuticals, Inc. Compounds and Methods for Treatment of Visceral Pain
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
WO2023059610A1 (en) 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
CN121987637A (zh) * 2026-03-18 2026-05-08 广东医科大学 Olorinab在制备治疗和/或预防缺血性心肌病的药物中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
CA2468794A1 (en) 2001-12-07 2003-06-19 Virginia Commonwealth University Treatment of neoplasia
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
CA2586011C (en) 2004-07-12 2011-07-19 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2613678A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
CN101238107A (zh) * 2005-06-02 2008-08-06 格兰马克药品股份有限公司 新的大麻素受体配体,含有该配体的药物组合物及其制备方法
CA2654246A1 (en) 2006-07-04 2008-01-10 Janssen Pharmaceutica N.V. Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Cb2 수용체를 조절하는 화합물
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
AU2007315848A1 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
EP2120938A4 (en) 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
JP5185924B2 (ja) 2007-03-16 2013-04-17 京セラ株式会社 誘電体磁器およびコンデンサ
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
EA201000046A1 (ru) 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102282147B (zh) 2009-01-28 2015-09-30 卡拉治疗学股份有限公司 二环吡唑并-杂环
EP2470508A1 (en) * 2009-08-28 2012-07-04 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX392150B (es) 2011-02-25 2025-03-21 Arena Pharm Inc Moduladores de receptores canabinoides.
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP5945554B2 (ja) 2011-02-25 2016-07-05 アリーナ ファーマシューティカルズ, インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス(カンナビノイド受容体モジュレーター)

Also Published As

Publication number Publication date
CO6852066A2 (es) 2014-01-30
CN103608343B (zh) 2019-02-01
US11560369B2 (en) 2023-01-24
DK3395812T3 (da) 2022-11-28
CA2827057A1 (en) 2012-08-30
EA201391233A1 (ru) 2014-02-28
AU2012222146B2 (en) 2017-05-11
KR20140025353A (ko) 2014-03-04
US10981895B2 (en) 2021-04-20
US20210380560A1 (en) 2021-12-09
EP4166552B1 (en) 2025-03-19
SG192817A1 (en) 2013-09-30
EP2678330A1 (en) 2014-01-01
US9458136B2 (en) 2016-10-04
CN103608343A (zh) 2014-02-26
KR102036932B1 (ko) 2019-10-25
AU2012222146A1 (en) 2013-09-19
EP3395812B1 (en) 2022-09-28
CL2013002436A1 (es) 2014-01-24
EP3395812A1 (en) 2018-10-31
IL227782A0 (en) 2013-09-30
MX2013009760A (es) 2014-06-11
IL227782A (en) 2017-02-28
JP2014506602A (ja) 2014-03-17
US20170144993A1 (en) 2017-05-25
EP4166552A1 (en) 2023-04-19
EA035989B1 (ru) 2020-09-09
US20140135345A1 (en) 2014-05-15
EP3395812B8 (en) 2022-11-02
BR112013021549A2 (pt) 2016-11-01
MY165767A (en) 2018-04-23
NZ614787A (en) 2014-08-29
CA2827057C (en) 2022-06-07
WO2012116276A1 (en) 2012-08-30
US10183930B2 (en) 2019-01-22
BR112013021549B1 (pt) 2022-01-11
ES2932441T3 (es) 2023-01-19
MX346533B (es) 2017-03-14
JP5945554B2 (ja) 2016-07-05
PH12013501726A1 (en) 2014-01-13
US20190308952A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
EP3395812B8 (en) Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
HUE066259T2 (hu) Intermedierek a C-terminális HSP90 inhibitorok elõállításához
ZA201305972B (en) Method for the preparation of biphephos
SG10201501575VA (en) Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
HUE037511T2 (hu) Eljárás toluol-diamin elõállítására dinitro-toluol hidrogénezésével
SG11201400939YA (en) Process for the preparation of methoxymelonal
ZA201403736B (en) Process for the preparation of sterol derivatives
ZA201303467B (en) Method for the preparation of high-purity pharmaceutical intermediates
PL2552925T3 (pl) Sposób wytwarzania azodikarbamidów zawierających krzem
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
IL221184A (en) A process for preparing 1-alkylated tetrazole 5 is produced
PL2681199T3 (pl) Sposób wytwarzania (-)-hupercyny A
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
HUE036284T2 (hu) Eljárás szilícium-karbid elõállítására
DK2429996T3 (en) Process for the preparation of histamine h3 receptor modulators
PT2702045T (pt) Método inovador para a preparação de etravirina
PT2390246T (pt) Processo para a preparação de aminaftona
HK1193088A (en) Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
ZA201303653B (en) Process for the preparation of gaseous synfuel
PL2598504T3 (pl) Sposób otrzymywania dimiracetamu
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
PL391682A1 (pl) Sposób otrzymywania ε-kaprolaktonu
ZA201208583B (en) Process for the preparation of hydroquinones
IL224304A (en) A process for making dichlorobulben
AU2011904710A0 (en) Device for Enhancing the Boarding of Aircraft